Test Price
4,000 AED✅ Home Collection Available
Liquid Biopsy Lung Cancer Test (NGS Panel) in UAE | 4000 AED
Executive Summary & Core Metrics
ISO 9001:2015 accredited processing guarantees 99.9% diagnostic sensitivity. This non-invasive liquid biopsy test screens for actionable mutations in ctDNA from a simple blood draw, guiding targeted lung cancer therapy. Results delivered in 21 working days with a telephonic clinical guidance session. VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily 8 AM to 11 PM. Direct insurance billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This liquid biopsy detects actionable mutations in cell‑free DNA (ctDNA) from a simple blood draw, guiding targeted therapy for lung cancer and monitoring treatment response. The test uses a comprehensive NGS panel covering key actionable genes and fusions such as EGFR, ALK, ROS1, BRAF, KRAS, and MET.
| Feature | Our Test | Closest Alternative |
|---|---|---|
| Method | NGS ctDNA Comprehensive Panel (actionable genes + fusions) | Single‑gene PCR or tissue NGS (invasive biopsy required) |
| Precision | 99.9% analytic sensitivity, allele frequency down to 0.1% | Variable, often 95–98% for tissue‑based hotspots |
| Turnaround | 21 working days – secure report with clinical interpretation | Typically 14–30 days, may lack actionable interpretation |
| Sample & Process | Blood – home collection, cold‑chain, ISO‑certified lab | Tissue block from hospital biopsy, no home collection |
Physician Insight & Safety Protocols
“As a lung cancer diagnostics specialist, I emphasize that every ctDNA result must be interpreted in the full clinical context—imaging, pathology, and patient history. This test empowers early detection of resistance, but it never replaces your oncologist’s judgment. You are not alone; we are here to guide every step.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Medication Advisory
Do not discontinue any prescribed cancer medication or adjust dosage without consulting your treating oncologist. This test is for monitoring and detection, not for emergency self‑management.
Exclusion Criteria & ER Red Flags
- A negative liquid biopsy does not exclude the presence of lung cancer; tissue biopsy remains the gold standard for initial diagnosis.
- Severe symptoms such as hemoptysis, dyspnea, or chest pain require immediate emergency care—do not delay.
- Recent blood transfusion or surgery may affect ctDNA levels; inform your laboratory.
- Baseline tissue biopsy may be required for first-time molecular profiling; discuss with your oncologist.
Patient FAQ & Clinical Guidance
1. How long until I receive my results?
Your results are delivered within 21 working days via secure online portal, with a telephonic clinical guidance session included at no extra cost. The laboratory processes all batches under ISO‑controlled workflows; the report highlights actionable mutations (EGFR, ALK, ROS1, etc.) to assist your oncology team.
2. Can this liquid biopsy replace a traditional tissue biopsy for lung cancer diagnosis?
Liquid biopsy can often supplement but not entirely replace tissue biopsy; a tissue sample remains the definitive method for initial diagnosis and molecular profiling. Your oncologist may recommend both tests to gain a comprehensive genomic picture, especially if tissue is insufficient or inaccessible.
3. Will my insurance cover this liquid biopsy test?
Insurance coverage varies by provider and plan. Our team can assist with pre-authorization and direct billing verification. Contact us on WhatsApp +971 54 548 8731 to check your coverage.
UAE Regulatory & Data Privacy Adherence
This service fully adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability.
Laboratory licensed under DHA Facility License Number: 1143, ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139). Physical Address: Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
Clinical & Logistical Metadata
| Test Name | Liquid Biopsy Lung Cancer Test (NGS Panel) |
| Price (AED) | 4,000 |
| Turnaround Time | 21 working days |
| Sample Type / Matrix | Peripheral blood (plasma ctDNA) |
| Methodology Used | Next-Generation Sequencing (NGS) – Comprehensive ctDNA Panel |
| ICD-10-CM Code | C34.9 |
| LOINC Code | 94498-5 |
| DHA Facility License & Laboratory Address | License 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians